Targeted cancer drugs finally living up to the hype

Targeted cancer drugs finally living up to the hype
Big pharmaceutical companies are backing so-called antibody-drug conjugates. (Image: Bloomberg)
Bloomberg
By Lisa JarvisCancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumours are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by the recent US$10.1 billion (NZ$16.5b) acquisition of ImmunoGen by AbbVie.If that trend sounds vaguely familiar, you have probably been following the pharma industry for too long. The field has gone through waves of hype and i...

More Bloomberg

Singapore becomes hot spot for M&A bankers hunting Asia deals
Finance

Singapore becomes hot spot for M&A bankers hunting Asia deals

The island is a magnet for parties interested in mergers and acquisitions.

Bloomberg 28 Jun 2024
Wall St backers see breakthrough moment for carbon offsets
Climate change

Wall St backers see breakthrough moment for carbon offsets

Promoters' big wins include Biden administration's blessing of the credits.

Bloomberg 22 Jun 2024
Nvidia’s rise to US$3 trillion fuels ‘Jensanity’ in the tech world
Technology

Nvidia’s rise to US$3 trillion fuels ‘Jensanity’ in the tech world

At Computex, cheering, chanting fans followed the billionaire everywhere.

Bloomberg 15 Jun 2024
Google's AI keeps hallucinating. Does anyone care?
Technology

Google's AI keeps hallucinating. Does anyone care?

Complacency over AI errors will only make the search experience worse.

Bloomberg 02 Jun 2024